SEC Form 4 · accession 0001144204-15-012374
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Klaus R Dr Veitinger
Director
Period of report
Feb 24, 2015
Accepted (ET)
Feb 26, 2015 · 9:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 24, 2015 | M | 632 | $21.50 | A | 2,798 | D | |
| Common Stock | Feb 24, 2015 | S | 632 | $222.50 | D | 2,166 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF2 | $21.50 | Feb 24, 2015 | M | 632 | D | — | Nov 16, 2022 | Common Stock | 632 | 9,536 | D |
Explanation of responses
- F1The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 13, 2014.
- F2All shares underlying this option have vested.